Compounds > aminoquinuride
Page last updated: 2024-12-06

aminoquinuride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID71166
CHEMBL ID87223
SCHEMBL ID321401
MeSH IDM0056695

Synonyms (44)

Synonym
CHEMBL87223
NSC12155 ,
n,n'-bis(4-amino-2-methyl-6-quinolinyl)urea
NCGC00013130
n,n'-bis(4-amino-2-methylquinolin-6-yl)urea
NSC ,
aminoquinuride
1PWP
DB04452
NCI12155
NCI60_000503
NCISTRUC2_001051
NCISTRUC1_001252
NCGC00096251-02
NCGC00096251-01
aminochinurid
1,3-bis(4-amino-2-methylquinolin-6-yl)urea
surfen
aminokinuridum
unii-08t7936572
aminoquinurida [inn-spanish]
urea, n,n'-bis(4-amino-2-methyl-6-quinolinyl)-
aminochincarbamidum
aminoquinuride [inn]
aminoquinuridum
aminoquinuridum [inn-latin]
n,n-bis(4-aminochinaldyl-6)harnstoff
08t7936572 ,
aminoquinurida
urea, 1,3-bis(4-amino-2-methyl-6-quinolyl)-
aminochinuridum
1,3-bis(4-amino-2-methyl-6-quinolyl)urea
3811-56-1
aminoquin carbamide
CCG-37349
NCGC00013130-02
bdbm50444748
n,n'-bis(4-amino-2-methyl-6-quinolyl)urea
aminoquinuride [who-dd]
aminoquinuride [mi]
SCHEMBL321401
DTXSID9046948
surfen-konzentrationen
Q471662
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency0.63100.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency7.94330.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency10.00000.031637.5844354.8130AID504865
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency1.00000.28189.721235.4813AID2326
Bloom syndrome protein isoform 1Homo sapiens (human)Potency14.12540.540617.639296.1227AID2528
DNA polymerase kappa isoform 1Homo sapiens (human)Potency6.30960.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.72080.005612.367736.1254AID624032
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency5.01190.316212.765731.6228AID881
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency5.01190.00638.235039.8107AID881
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)31.00000.00020.850210.0000AID1060799
Botulinum neurotoxin type A Clostridium botulinumIC50 (µMol)7.20000.50003.16927.2000AID1060800
Matrix metalloproteinase-9Homo sapiens (human)IC50 (µMol)100.00000.00000.705310.0000AID1060798
Lethal factorBacillus anthracisIC50 (µMol)3.20000.09702.85976.0000AID1060802
Lethal factorBacillus anthracisKi0.50000.00701.95814.9000AID1060806
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)IC50 (µMol)14.50000.20005.066710.0000AID1260080; AID1559772
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)IC50 (µMol)14.50000.20005.066710.0000AID1260080; AID1559772
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)3.20000.00061.525710.0000AID1060802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (74)

Processvia Protein(s)Taxonomy
DNA repairEyes absent homolog 2Homo sapiens (human)
chromatin remodelingEyes absent homolog 2Homo sapiens (human)
mesodermal cell fate specificationEyes absent homolog 2Homo sapiens (human)
striated muscle tissue developmentEyes absent homolog 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandEyes absent homolog 2Homo sapiens (human)
mitochondrial outer membrane permeabilizationEyes absent homolog 2Homo sapiens (human)
anatomical structure developmentEyes absent homolog 2Homo sapiens (human)
positive regulation of DNA repairEyes absent homolog 2Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandEyes absent homolog 2Homo sapiens (human)
cell differentiationEyes absent homolog 2Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
skeletal system developmentMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of protein phosphorylationMatrix metalloproteinase-9Homo sapiens (human)
proteolysisMatrix metalloproteinase-9Homo sapiens (human)
apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
embryo implantationMatrix metalloproteinase-9Homo sapiens (human)
cell migrationMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-9Homo sapiens (human)
macrophage differentiationMatrix metalloproteinase-9Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-9Homo sapiens (human)
cellular response to reactive oxygen speciesMatrix metalloproteinase-9Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of DNA bindingMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
ephrin receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of keratinocyte migrationMatrix metalloproteinase-9Homo sapiens (human)
cellular response to lipopolysaccharideMatrix metalloproteinase-9Homo sapiens (human)
cellular response to cadmium ionMatrix metalloproteinase-9Homo sapiens (human)
cellular response to UV-AMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaMatrix metalloproteinase-9Homo sapiens (human)
regulation of neuroinflammatory responseMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of receptor bindingMatrix metalloproteinase-9Homo sapiens (human)
response to amyloid-betaMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney developmentMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cation channel activityMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-9Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
fibroblast proliferationGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
cellular response to prostaglandin E stimulusGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
cellular response to catecholamine stimulusGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
signal transductionGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
Ras protein signal transductionGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
cell population proliferationGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
sensory perception of tasteGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
retina development in camera-type eyeGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
cellular response to prostaglandin E stimulusGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
cellular response to catecholamine stimulusGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
magnesium ion bindingEyes absent homolog 2Homo sapiens (human)
protein bindingEyes absent homolog 2Homo sapiens (human)
histone H2AXY142 phosphatase activityEyes absent homolog 2Homo sapiens (human)
protein tyrosine phosphatase activityEyes absent homolog 2Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
protein transmembrane transporter activityBotulinum neurotoxin type A Clostridium botulinum
endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
protein bindingMatrix metalloproteinase-9Homo sapiens (human)
collagen bindingMatrix metalloproteinase-9Homo sapiens (human)
peptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metallopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-9Homo sapiens (human)
identical protein bindingMatrix metalloproteinase-9Homo sapiens (human)
protein bindingGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
G-protein beta-subunit bindingGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
GTPase activityGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
protein bindingGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
protein-containing complex bindingGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
GTPase bindingGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
signaling receptor complex adaptor activityGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
nucleoplasmEyes absent homolog 2Homo sapiens (human)
mitochondrionEyes absent homolog 2Homo sapiens (human)
cytosolEyes absent homolog 2Homo sapiens (human)
nucleusEyes absent homolog 2Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
extracellular regionMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
collagen-containing extracellular matrixMatrix metalloproteinase-9Homo sapiens (human)
extracellular exosomeMatrix metalloproteinase-9Homo sapiens (human)
tertiary granule lumenMatrix metalloproteinase-9Homo sapiens (human)
ficolin-1-rich granule lumenMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
membraneGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
extracellular exosomeGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
heterotrimeric G-protein complexGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2Homo sapiens (human)
lysosomal membraneGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
cytosolGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
membraneGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
synapseGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
extracellular exosomeGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
photoreceptor disc membraneGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
extracellular vesicleGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
heterotrimeric G-protein complexGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
cytoplasmGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID44315Ability to inhibit binding of radiolabeled C5a anaphylatoxin to intact membrane bound receptor from human neutrophils.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding.
AID261414Inhibition of PP2C alpha at 100 uM2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Discovery of protein phosphatase 2C inhibitors by virtual screening.
AID222480Compound was tested for the inhibition of fMLF- induced human neutrophil activation1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding.
AID1559772Inhibition of G-protein beta1gamma2 (unknown origin) by flow cytometry2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Heterotrimeric G Proteins as Therapeutic Targets in Drug Discovery.
AID1060799Inhibition of human MMP-1 after 60 mins by FRET assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Small molecule inhibitors of anthrax lethal factor toxin.
AID1060806Competitive inhibition of Bacillus anthracis lethal factor2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Small molecule inhibitors of anthrax lethal factor toxin.
AID1060800Inhibition of Clostridium bolulinum BoNT/A assessed as cleavage of MOCAc-Lys-Lys-Val-Tyr-Pro-Tyr-Pro-Met-Glu-Lys(Dnp)-NH2 after 40 mins by FRET assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Small molecule inhibitors of anthrax lethal factor toxin.
AID261416Inhibition of PP2A2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Discovery of protein phosphatase 2C inhibitors by virtual screening.
AID580534Antimicrobial activity against Bacillus anthracis Sterne vegetative cells by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.
AID1060802Inhibition of Bacillus anthracis lethal factor assessed as MCA-KKVYPYPME[dnp]K amide cleavage after 30 mins by fluorescence plate reader analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Small molecule inhibitors of anthrax lethal factor toxin.
AID261419Inhibition of PP1 at 100 uM2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Discovery of protein phosphatase 2C inhibitors by virtual screening.
AID222479Compound was tested for the inhibition of C5a- induced human neutrophil activation1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding.
AID225698Ability to inhibit C5a-induced release of azurophilic granular constituent myeloperoxidase (MPO) from intact neutrophils1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding.
AID580533Antimicrobial activity against Bacillus anthracis Sterne spores by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.
AID1060798Inhibition of human MMP-9 after 60 mins by FRET assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Small molecule inhibitors of anthrax lethal factor toxin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (24.00)18.7374
1990's1 (4.00)18.2507
2000's3 (12.00)29.6817
2010's11 (44.00)24.3611
2020's4 (16.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.91 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.00%)6.00%
Case Studies3 (12.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (84.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycine
[no description available]		2.2510alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		4.31190isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2,4-dinitrophenol
2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed). dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.. 2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.		2.0510dinitrophenolallergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.0510aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source. lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.		2.2510aromatic primary alcohol;
furans;
indazoles		antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.0510C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
quinoline
[no description available]		1.9310azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinolines
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		2.2510indazole
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.0510glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
4',6-bis(2'imidazolinyl-4',5'-h)-2-phenylindole
4',6-bis(2'imidazolinyl-4',5'-H)-2-phenylindole: used to produce distinct fluorescent bands in human chromosomes; structure		2.0510
1,2-di(5-amidino-2-benzofuranyl)ethane
1,2-di(5-amidino-2-benzofuranyl)ethane: preferential inhibitor of bovine factor Xa; structure given in first source		2.0510
chaetochromin
chaetochromin: from Chaetomium spp.; RN given refers to chaetochromin A		2.0310
gallein
gallein: do not confuse with gallin; structure. gallein : A xanthene dye that is fluoran carrying four hydroxy substituents at positions 3', 4', 5' and 6'.		3.35102-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorochrome;
G-protein-coupled receptor antagonist;
histological dye
2-(4-amidinophenyl)-1-benzofuran-5-carboxamidine
2-(4-amidinophenyl)-1-benzofuran-5-carboxamidine: structure given in first source		2.0510
mbx 1066
MBX 1066: structure in first source		2.0510
dimethyloxalylglycine
dimethyloxallyl glycine: structure in first source		2.2510glycine derivative;
methyl ester;
secondary carboxamide		EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor;
neuroprotective agent
genistein
[no description available]		2.25107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
sulfur
Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.		2.0410chalcogen;
nonmetal atom		macronutrient
mbx 1090
[no description available]		2.0510
ym-254890
YM-254890: structure in first source		3.3510
FR900359
FR900359: G-protein inhibitor from Ardisia crenata sims that shows inhibition of platelet aggregation and decrease of blood pressure		3.3510cyclodepsipeptide
ly-146032
[no description available]		2.0510heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
heparitin sulfate
Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.		3.5170
chondroitin sulfates
Chondroitin Sulfates: Derivatives of chondroitin which have a sulfate moiety esterified to the galactosamine moiety of chondroitin. Chondroitin sulfate A, or chondroitin 4-sulfate, and chondroitin sulfate C, or chondroitin 6-sulfate, have the sulfate esterified in the 4- and 6-positions, respectively. Chondroitin sulfate B (beta heparin; DERMATAN SULFATE) is a misnomer and this compound is not a true chondroitin sulfate.		2.6620
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.0510cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Asthma, Bronchial
[description not available]		03.1710
Cardiac Failure
[description not available]		03.1710
Benign Neoplasms
[description not available]		03.4420
Blood Clot
[description not available]		03.1710
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		03.1710
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		03.1710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.4420
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		03.1710
Astrocytoma, Grade IV
[description not available]		02.2110
Glial Cell Tumors
[description not available]		02.2110
Invasiveness, Neoplasm
[description not available]		02.2110
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.2110
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.2110
Mucopolysaccharidosis
[description not available]		02.3110
Mucopolysaccharidoses
Group of lysosomal storage diseases each caused by an inherited deficiency of an enzyme involved in the degradation of glycosaminoglycans (mucopolysaccharides). The diseases are progressive and often display a wide spectrum of clinical severity within one enzyme deficiency.		02.3110
Allergic Encephalomyelitis
[description not available]		02.1710
Innate Inflammatory Response
[description not available]		02.1710
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1710
Bessel-Hagen Disease
[description not available]		02.5220
Aberrant Tissue
[description not available]		02.0810
HIV Coinfection
[description not available]		02.0510
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.0510
Allergic Reaction
[description not available]		01.9310
Diseases of Immune System
[description not available]		01.9310
Dermatoses
[description not available]		01.9310
Hypersensitivity
Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.		01.9310
Immune System Diseases
Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.		01.9310
Skin Diseases
Diseases involving the DERMIS or EPIDERMIS.		01.9310
Allergy, Drug
[description not available]		02.3620
Granulomas
[description not available]		02.3720
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		02.3620
Drug Hypersensitivity
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.		02.3620
Granuloma
A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.		02.3720
Delayed Hypersensitivity
[description not available]		01.9610
Tuberculoma
A tumor-like mass resulting from the enlargement of a tuberculous lesion.		01.9610
Arthus Phenomenon
[description not available]		01.9510
Dermatitis Medicamentosa
[description not available]		01.9710
Autoimmune Diabetes
[description not available]		01.9710
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		01.9710